Guillain-Barre syndrome (GBS) is the leading cause of acute paralysis that can 
potentially affect all of the human population. GBS is believed to be an 
immune-mediated disease, possibly triggered by a recent infection, and driven by 
an immune attack targeting the peripheral nervous system. GBS can be divided 
into several subtypes depending on the phenotype, pathophysiology, and 
neurophysiological features. Unfortunately, morbidity and mortality rates are 
still high despite the current understanding of the pathophysiology and 
available treatment options. Additional research is still needed to shed more 
light into the pathogenesis for a better understanding and treatment of this 
condition.